BUSINESS
Wockhardt hopes to complete Phase III trials for Zaynich by Q1 of 2025
So far it has supplied the compound to 30 patients for compassionate use with range of life-threatening infections
BUSINESS
Lupin down almost 5% on worries of increased competition in US inhalation market
US-based Amphastar has got FDA nod for Albuterol Sulfate inhalation aerosol, which is the second largest revenue contributor to Lupin's American revenue
BUSINESS
Sun Pharma shares fall 4% as management guides for single-digit revenue growth
Notably, the management said that spending on R&D expenses will rise to 10% of revenue from 6-7% to aid its specialty portfolio
BUSINESS
Wockhardt planning new funding round
The company had completed a QIP of Rs 480 crore in March 2024.The company board plans to make a decision on the fundraise at a meeting on May 28.
BUSINESS
Biocon’s formulations business to outpace API share soon: CEO
Formulations will focus on peptides, a class of drugs that among other things hels in weight loss, said the MD and CEO
BUSINESS
Medanta Q4 net profit up 25% to Rs 127.3 crore
Medanta Q4:The hospital operator's revenue from operations came in at Rs 808 crore, a 14 percent rise from the year-ago period's Rs 707 crore.
BUSINESS
Biocon bets on weight-loss drugs as major growth engine for the business
Weight loss products have driven revenues in recent years for global giants like Novo Nordisk and Eli Lilly
BUSINESS
Open to market Eli Lilly’s weight loss drugs in India: Cipla CEO
Currently Cipla has the right to sell, promote and distribute two diabetes drugs of Eli Lilly in India
BUSINESS
Dr Reddy’s to launch over 20 products in US in FY25
Dr Reddy’s reported better-than-expected net profit of Rs 1,307 crore for the March quarter, up 36 percent from the year-ago period
BUSINESS
Specialty chemicals business faces high competition, dumping from Chinese players: SRF Ltd
The management believes that recovery will pick up pace in the second half of FY25
BUSINESS
Ajanta Pharma expects its overall FY25 revenue growth to be in the low teens
The company anticipates the fastest growth to come from its dermatology portfolio, followed by ophthalmology and cardiology.
BUSINESS
Ajanta Pharma Q4 net profit jumps 66% to Rs 202.72 cr, approves buyback of shares
The Mumbai-based pharma major's revenue came in at Rs 1,054.08 crore, up 20 percent from Rs 881.84 crore a year back.
BUSINESS
Eli Lilly lifts 2024 revenue guidance by $2 billion on weight-loss pills demand
For Q1 2024, worldwide Mounjaro revenue was $1.81 billion compared with $568.5 million in Q1 2023
BUSINESS
Laurus Labs: CDMO services key to improved prospects, say analysts
In FY24, CDMO sales declined 57% YoY to Rs 9.2 billion
BUSINESS
Will improve EBITDA margin in FY25: Laurus Labs
The company also expects an improvement in its net debt leverage and working capital in FY25.
BUSINESS
Divi's Labs inks long-term supply deal, plans up to Rs 700-crore capacity addition
The investment will be funded from internal accruals.
BUSINESS
High single digit to low double digits revenue projections for FY 25: Syngene CEO
Management expressed positive long-term outlook for the sector and expressed confidence in Syngene's sustained performance on the back of improved fund flows into US biotech in the latter part of the year.
BUSINESS
US FDA releases details of OAI observations at Sun Pharma’s Dadra plant
Dadra's specialization lies in the production of oral solid dosage forms and the manufacture of the blockbuster drug Revlimid, a vital revenue driver for Sun Pharma's generics segment.
BUSINESS
Healthcare, pharma deal values fall 67% YoY in March quarter: GT Bharat
The quarter also reported four IPOs totaling $466 million, a doubling in volumes compared to the previous quarter
TRENDS
Elections 2024: What kind of healthcare do the party manifestos promise?
The National Health Policy, 2017, had recommended that govt expenditure on public health should be at least 2.5 percent of GDP. But it was only 2.1 percent as of 2022-23. Inadequate investment in public health can hinder healthcare accessibility and negatively impact health indicators.
BUSINESS
US FDA releases details of observations on Alkem's Baddi Plant
The US FDA had conducted an inspection of the facility last month and had made ten procedural observations, including issues with cleanliness and the company's failure to keep written documents on quality control procedures.
BUSINESS
Steady US sales to bring a healthy quarter for pharma sector
After witnessing consistent double-digit growth in branded formulations business in recent years, growth in the domestic formulation segment has moderated to high single digits
BUSINESS
Lupin, Glenmark, Natco recall products from US markets
Lupin recalled 26,352 bottles of Rifampin capsules, used in the treatment of tuberculosis
BUSINESS
Indian pharmaceutical market registers 9.5% growth in March
While most of the corporates have shown double digit value growth, unit growth remains a challenge for the Indian pharma market, according to analysts
